Graft Vs Host Disease Clinical Trial
Official title:
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
In this trial, the investigators will begin to explore the possibility that, as in mice, JAK1/2 inhibition with hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) while retaining engraftment and Graft-versus-Leukemia (GVL). Both preclinical and clinical data suggest that inhibition of IFNy and IL-6, directly and using downstream JAK Inhibitors, may be an effective strategy to decrease toxicities and improve disease control for patients undergoing Allogeneic HSCT. Baricitinib, as a JAK1/2 inhibitor, has shown superiority to other JAK inhibitors in preclinical GVHD models. The purpose of this phase I clinical trial is to determine the safety of baricitinib with HSCT measured by the effect on engraftment and grade III-IV acute graft-versus-host-disease (aGVHD).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Withdrawn |
NCT04728646 -
Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
|
Phase 4 | |
| Suspended |
NCT01972438 -
A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01221766 -
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
|
N/A | |
| Recruiting |
NCT01764100 -
Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)
|
Phase 1 | |
| Completed |
NCT00760981 -
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
|
Phase 1 | |
| Terminated |
NCT00298324 -
Myfortic - Treatment for Extensive cGvHD
|
Phase 3 | |
| Completed |
NCT00224874 -
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
|
Phase 2 | |
| Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
| Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
| Recruiting |
NCT05111834 -
IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms
|
N/A | |
| Completed |
NCT02841995 -
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
|
Phase 2 | |
| Recruiting |
NCT06143501 -
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
|
||
| Recruiting |
NCT04622956 -
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01042509 -
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
|
N/A | |
| Terminated |
NCT00117702 -
Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus
|
Phase 2/Phase 3 |